Bridging the Gap in Cancer Diagnostics with Accurate, Accessible, and Innovative Tests

Canary Oncoceutics is a pioneering leader in cancer diagnostics, known for its flagship product – Canary Acuity™, the most comprehensive genomic profiling test available on the market today. This highly sensitive and accurate test analyzes 1,091 cancer-related genes in both solid tumors and hematological malignancies. It has transformed cancer care by offering unparalleled insight into the molecular underpinnings of cancer, enabling clinicians to personalize treatment strategies based on each patient’s unique genetic and tumor profile. In addition to its comprehensive genomic profiling services, Canary Oncoceutics also offers smaller next-generation sequencing (NGS) panels that focus on a select number of genes for cancer diagnosis and treatment planning.

Focused NGS panels can be equally effective in identifying clinically actionable mutations

Targeted panels are designed to focus on a curated list of genes most relevant to specific cancer types, correlating with approved therapies. For instance, mutations in the EGFR, ALK, RET, and ROS1 are well-established targets in lung cancer, while KRAS, NRAS, and BRAF mutations are key targets in colorectal cancer. By focusing on these actionable biomarkers, these panels can still provide valuable information to aid treatment decisions. Importantly, the key advantage of these targeted panels is their cost-effectiveness. Comprehensive genomic profiling evaluates a large number of genes and generates an enormous amount of data, which inherently makes it more expensive both in the terms of the testing itself and the associated data analysis. In contrast, compact panels are generally more affordable by narrowing the focus to the most clinically relevant genes, simplifying the data analysis process. By bridging the affordability gap, focused panels improve access to essential genomic testing for a broader patient population, particularly those from lower-income communities.

Unlocking the power of compact panels in cancer diagnostics

Canary Oncoceutics offers various compact NGS panels suitable for patients at the beginning of their cancer treatment journey, or for those diagnosed with common cancer types that have limited or known driver mutations. Both Canary Focus™ (for solid tumors and hematological malignancies) and Canary Stat™ (liquid biopsy test) examine single nucleotide variants, insertions, deletions, amplifications, and gene fusions across 140 key cancer-related genes, including microsatellite instability (MSI) and homologous recombination deficiency (HRD). The integration of pharmacogenomic variants, which influence drug response and metabolism, in these tests is revolutionary, as it enables therapy to be individualized based on the patient’s genetic and tumor profile. Besides serving as an alternative to tissue biopsy testing, Canary Stat™ is also well-suited for longitudinal monitoring, such as tracking disease progression, evaluating treatment response, and detecting minimal residual disease. For cancers where mutations in homologous recombination repair (HRR) genes play a key role in treatment response, such as breast, ovarian, and prostate cancers, Canary Oncoceutics offers Canary HRD™. This test specifically evaluates 41 HRR genes and calculates an HRD score to identify patients who may benefit from certain targeted therapies, with HRD-positive tumors being more likely to respond to PARP inhibitors like olaparib. Additionally, this test can offer insights into cancer risk by identifying germline mutations in genes like BRCA1/2, known risk factors for certain cancers. The use of deep sequencing in these tests, with 2,000× coverage for tissue biopsy and 20,000× coverage for liquid biopsy tests, surpasses most competing tests. This enhanced sequencing is a key component that enables the identification of low-allele frequency mutations with high confidence and accuracy.

Decoding genetic insights through hereditary cancer risk profiling

Beyond tumor profiling, Canary Oncoceutics also offers the Canary Stat Heredit™, which is designed to assess hereditary cancer risk, providing valuable information for both patients and their families. This test evaluates 93 carefully curated genes for a variety of genetic alterations, including single nucleotide variants, insertions, deletions, amplifications, and gene fusions. By identifying mutations associated with cancer risk, this test plays a crucial role in supporting early cancer detection, enabling the development of personalized preventive strategies, and conducting thorough family risk assessments. Additionally, the Canary Stat Heredit™ test helps guide the selection of targeted therapies, while the inclusion of pharmacogenomic variants aids in refining drug selection and dosing for the patient. With an extensive portfolio of diagnostic tests, including advanced tumor profiling, minimally invasive liquid biopsy, and hereditary cancer risk assessment, Canary Oncoceutics offers clinicians the flexibility to select the most appropriate test based on the patient’s clinical needs. These highly sensitive and accurate tests, powered by artificial intelligence (AI) and machine learning (ML), provide actionable insights that can guide clinical decision-making. Performed in state-of-the-art laboratories accredited by the College of American Pathologists (CAP) and certified under the Clinical Laboratory Improvement Amendments (CLIA), these tests adhere to the highest standards of quality and reliability. This ensures that cancer patients not only receive the most effective treatments based on precise, personalized information, but also avoid unnecessary delays in diagnosis and treatment. Moreover, by making genomic testing more affordable, Canary Oncoceutics helps to alleviate the financial burden associated with cancer diagnosis, ensuring that cutting-edge care is accessible to all patients.